FONDATION-IPSEN
23.5.2017 07:32:05 CEST | Business Wire | Press release
The Fondation IPSEN (1) contributes to the development and dissemination of scientific knowledge by fostering interaction between scientists and clinicians. The Fondation IPSEN Endocrine Regulations Prize (2) will be presented today at the ECE (European Congress of Endocrinology) in Lisbon. An international jury (3) chaired by Professor Iain Robinson (National Institute for Medical Research, London, UK ), awarded the prize to Bruce Mc Ewen for his pioneering work on glucocorticoids, stress and neuronal degeneration.
The Fondation IPSEN(1) contributes to the development and dissemination of scientific knowledge by fostering interaction between scientists and clinicians from different backgrounds. Created in 2002, the Endocrine Regulations Prize(2) of the Fondation IPSEN awards renowned specialists who made breakthrough discoveries or significant progress in the field. Pr Bruce McEwen has been awarded by an international jury(3) for his pioneering work on glucocorticoids, stress and neuronal degeneration. The prize will be presented at the ECE (European Congress of Endocrinology), followed by a lecture given by Bruce McEwen.
During his talk, Bruce McEwen will discuss about the role of the steroid
hormones that are produced in the brain which mediate every aspect of
brain function. This has broadened the definition of
‘neuroendocrinology’ to include the reciprocal communication between the
brain and the body via hormonal and neural pathways.
The brain is
the central organ of stress and adaptation to stress because it
perceives and determines what is threatening, as well as the behavioural
and physiological responses to the stressor. The adult and developing
brain possess remarkable structural and functional plasticity in
response to stress, including neuronal replacement, dendritic
remodelling, and synapse turnover. Stress causes an imbalance of neural
circuitry subserving cognition, decision-making, anxiety and mood. This
imbalance, in turn, affects systemic physiology via neuroendocrine,
autonomic, immune and metabolic mediators. In the short term, as for
increased fearful vigilance and anxiety in a threatening environment,
these changes may be adaptive. But, if the danger passes and the
behavioural state persists along with the changes in neural circuitry,
such maladaptation may need intervention with a combination of
pharmacological and behavioural therapies, as is the case for chronic
anxiety and depression. Moreover, adverse early-life experience, produce
lasting effects on brain and body over the life-course via epigenetic
mechanisms. While prevention is most important, the plasticity of the
brain gives hope for therapies that take into consideration brain–body
interactions.
Biography
Bruce S. McEwen obtained his Ph.D. in Cell
Biology in 1964 from The Rockefeller University.
He is a member
of the US National Academy of Sciences, the National Academy of
Medicine, and the American Academy of Arts and Sciences. He served as
President of the Society for Neuroscience in 1997-98. As a
neuroscientist and neuroendocrinologist, McEwen studies
environmentally-regulated, variable gene expression in brain, mediated
by circulating steroid hormones and endogenous neurotransmitters in
relation to brain sexual differentiation and the actions of sex and
stress hormones on the adult brain. His laboratory discovered adrenal
steroid receptors in the hippocampus in 1968 that was the gateway for
discovering effects of circulating hormones on cognitive function, mood
regulation and other CNS functions. His laboratory combines molecular,
anatomical, pharmacological, physiological and behavioral methodologies
and relates their findings to human clinical information. His current
research focuses on stress effects on amygdala and prefrontal cortex, as
well as hippocampus, and his laboratory also investigates sex hormone
effects and sex differences in these brain regions involved in cognitive
function and mood regulation. He served on the MacArthur Foundation
Research Network on Socioeconomic Status and Health, in which he has
helped to reformulate concepts and measurements related to stress and
stress hormones in the context of human societies. This led to the
concept of “allostatic load and overload” that describes the wear and
tear on the body and brain from chronic stress and related life style
behaviors that lead to dysregulation of physiological stress pathways
that are normally protective.
He is also a member of the National
Council on the Developing Child which focuses on biological embedding of
early life experiences and promoting healthy brain development.
He
is the co-author of a book with science writer, Elizabeth Lasley, for a
lay audience called “The End of Stress as We Know It”, published in
2002, and “The Hostage Brain” with science writer, the late Harold M.
Schmeck, Jr., published in 1994.
(1) The Fondation IPSEN
Established in 1983 under the
aegis of the Fondation de France, the ambition of the Fondation IPSEN is
to initiate a reflection about the major scientific issues of the
forthcoming years. The long-standing mission of the Fondation IPSEN is
to contribute to the development and dissemination of scientific
knowledge by fostering interaction between scientists and clinicians. It
has developed an important international network of scientific experts
who meet regularly at meetings known as Colloques Médecine et
Recherche
, dedicated to three main topics: neurosciences,
endocrinology and cancer science. Moreover the Fondation IPSEN has
started several series of meetings in partnership with the Salk
Institute, the Karolinska Institute as well as with the journals Cell
and Science
. The Fondation IPSEN produced several hundred
publications and more than 250 scientists have been awarded prizes and
grants.
www.fondation-ipsen.org
(2) The Endocrine Regulations Prize laureates
Created
in 2002, this Prize of
the Fondation Ipsen
has been
awarded to following the renowned specialists: Wylie VALE
(2002), Robert
LEFKOWITZ
(2003), Pierre CHAMBON
(2004), Thomas HÖKFELT
(2005), Roger CONE
(2006), William CROWLEY
(2007), Ronald
EVANS
(2008), Gilbert VASSART
(2009), Shlomo MELMED
(2010), Paolo SASSONE-CORSI
(2011), Jeffrey M. FRIEDMAN
(2012), Bert O’MALLEY
(2013), Maria I. NEW
(2014), C.
Ronald Kahn
(2015) and John W. FUNDER
(2016).
(3) Members of the jury
Iain ROBINSON
(National
Institute for Medical Research, London, UK)
, President
Xavier
BERTAGNA
(Hôpital Cochin, Paris, France)
Felipe
CASANUEVA
(University of Santiago de Compostela, Santiago de
Compostela, Spain)
Michael CONN
(Texas Tech
University Health Sciences Center, El Paso, USA)
Ezio GHIGO
(Ospedale Molinette, Turin, Italy)
Ilpo HUHTANIEMI
(Imperial
College Faculty of Medicine, London, UK)
Gérard KARSENTY
(Columbia
University Medical Center, New York, USA)
Paul KELLY
(Faculté
de Médecine Necker Enfants Malades, Paris, France)
Stafford
LIGHTMAN
(University of Bristol, Bristol, UK)
Günter
STALLA
(Max Planck Institute of Psychiatry, München, Germany
Phyllis
WISE
(University of Illinois, Urbana, USA).
View source version on businesswire.com: http://www.businesswire.com/news/home/20170522005878/en/
Contact:
Fondation IPSEN
Yannick TANGUY, Tel. : +33 (0)1 58 33 50 00
E-mail
: fondation@ipsen.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lebrikizumab Delivered Significant Skin Clearance and Improved Disease Severity in Children With Moderate-to-severe Atopic Dermatitis16.3.2026 11:53:00 CET | Press release
Almirall announces positive, top-line results from Phase 3 ADorable-1 trialADorable-1 met co-primary efficacy endpoints, with 63% of paediatric patients achieving meaningful skin improvement (EASI-75) and 44% reaching clear or almost clear skin (IGA 0,1) at week 16.Key secondary endpoints showed significant itch relief (Pruritus NRS ≥4 point improvement), reduced overall disease severity (EASI-90) and improved quality of life (CDLQI ≥6-Point Improvement) in children and adolescents with moderate-to-severe atopic dermatitis treated with lebrikizumab.Skin conditions can have a profound physical and emotional impact on people’s lives1, and Atopic Dermatitis (AD) peaks in childhood – with around 60% of cases appearing within the first year of life2. Almirall, S.A. (ALM), a global biopharmaceutical company focused on medical dermatology, today announced positive, top-line results from the pivotal Phase 3 ADorable-1 trial evaluating efficacy and safety of lebrikizumab for children and adoles
Experian Marks a Breakthrough in Consumer AI with the Next Evolution of Its Virtual Assistant16.3.2026 11:00:00 CET | Press release
Smarter, more adaptive assistant advances personalized, conversational financial guidance powered by trusted data Experian today unveiled the next evolution of the Experian Virtual Assistant, EVA™, a significant advancement in its Consumer First AI strategy that expands personalized, conversational financial guidance to millions of consumers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260316538160/en/ Experian today unveiled the next evolution of the Experian Virtual Assistant, EVA™. “This next generation of EVA reflects the direction of our consumer AI strategy,” said Debbie Hsu, Executive Vice President of Product, Experian Consumer Services. “We are bringing together conversational AI, personalization, and our trusted data foundation to deliver guidance that is intuitive, relevant, and actionable. Our focus is on helping consumers make smarter financial decisions in ways that feel simple and empowering.” Built to scal
Triton Partners Successfully Closes Fund 6 at €5.5 Billion Target16.3.2026 08:00:00 CET | Press release
Triton Partners today announces the successful close of its sixth flagship mid-market fund (“T6” or “the Fund”) on target at €5.5 billion, the largest fund to date for Triton. The Fund has raised capital from new and existing investors globally, underscoring the continued confidence of Limited Partners in Triton’s European mid-market strategy and the Firm’s ability to build better businesses. Triton’s Mid-Market buyout (TMM) strategy focuses on its core sectors of industrial technology, business services and healthcare. As a responsible owner of choice, T6 will invest where its market and investment insights provide an edge, positioning the firm to capitalise on attractive opportunities, supported by the Accelerator Unit, Europe’s largest value creation team. T6 seeks to maintain the strong performance of previous funds, all having achieved top quartile returns. Reflecting this consistent track record, Triton was recently named as one of three European managers in the HEC global univer
Syngenta deepens research capabilities with QuantumBasel partnership16.3.2026 08:00:00 CET | Press release
At the World Agri-Tech Innovation Summit, Syngenta, a global leader in agricultural innovation, today announced it is exploring how quantum computing can help farmers meet the growing demands of food production in a changing climate. The company has partnered with QuantumBasel, Switzerland's first commercial quantum computing hub, to apply quantum technologies to agricultural research and development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260316646014/en/ Ion trap, which uses electromagnetic fields to confine and control ions for use as quantum bits (qubits). Farmers worldwide face mounting pressure to produce more food sustainably amid unpredictable weather and evolving pest and disease challenges. Meeting these demands requires new scientific approaches that go beyond what classical computing can deliver, particularly when it comes to understanding the complex molecular and biological systems that underpin crop sc
NTT DATA Launches GCC Innovation Acceleration Program to Support Innovation Creation by Global Companies16.3.2026 04:30:00 CET | Press release
NTT DATA, a global leader in AI, digital business and technology services, today announced the launch of its GCC Innovation Acceleration Program. This is designed to support global companies rapidly establishing and scaling their strategic offshore hubs in India, including Global Capability Centers (GCC) and other innovation and delivery hubs. Launched in October 2025, the program aims to support more than 50 companies over the next three years. The demand for highly skilled IT personnel has expanded globally, and as a result, companies are increasingly using overseas bases to meet innovation needs. NTT DATA identified India as a stand-out market to launch the GCC Innovation Acceleration Program because of its abundance of talent and strong technical capabilities. India’s Global Capability Center ecosystem, delivering IT services and back-office functions to multinationals, is poised for strong growth of nearly 70%, targeting $110 billion in 2030 from the current $65 billion, according
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
